Medtronic’s Sphere-9 Catheter is an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high-density mapping catheter for the treatment of persistent atrial fibrillation (AFib).

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

The Global Radiofrequency Ablation Device Market is expected to grow at 9.35% CAGR from 2025 to 2032. The latest Research report published by Coherent Market Insights with the title "An Increase ...

St. David's in Austin is the first in country to use new dual catheter to fix heart flutter and AFib at the same time.

Medtronic announced today that it brought its Affera mapping and ablation system into clinical use for the first time in Sweden.

Health Canada has issued a licence for Medtronic’s Symplicity Spyral ... a key contributor to hypertension, utilising radiofrequency ablation. The approval from Health Canada is based on ...

Using a temperature-controlled ablation system for ventricular tachycardia is safe and effective, says new study.

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success was offset by weaker sales from its medical-surgical business.

We expect Medtronic's new neuromodulation technology, neurovascular devices and insulin pumps, the introduction of pulsed field ablation for the atrial fibrillation market, and transcatheter heart ...

Full Year EPS Guidance: $5.44 to $5.50. Medtronic PLC (NYSE:MDT) reported its ninth consecutive quarter of mid-single-digit revenue growth, with strong performances in Cardiac Ablation Solutions, ...